Dynavax and Clover Biopharmaceuticals Announce Research Collaboration to Evaluate Coronavirus (COVID-19) Vaccine Candidate with CpG 1018 Adjuvant

Dynavax is providing technical expertise and the companys proprietary toll-like receptor 9 (TLR9) agonist adjuvant, CpG 1018, to support this initiative.